Telix Pharmaceuticals Limited (TLX)
(Delayed Data from NSDQ)
$10.93 USD
+0.88 (8.76%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.92 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Telix Pharmaceuticals Limited has a market cap of $3.40B, which represents its share price of $10.05 multiplied by its outstanding shares number of 338.44M. As a mid-cap company, TLX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TLX 10.93 +0.88(8.76%)
Will TLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
UBS Maintains Buy Rating on TLX, Lowers Target Price to $20 | TLX Stock News
Telix Pharmaceuticals price target lowered by $3 at UBS
Is TLX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rising 0.7%
UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley